×
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
QQQ   299.33 (+2.77%)
AAPL   143.78 (+2.32%)
MSFT   265.90 (+1.29%)
FB   191.63 (+4.24%)
GOOGL   2,155.85 (+1.88%)
AMZN   2,221.55 (+4.03%)
TSLA   707.73 (+7.43%)
NVDA   178.51 (+5.16%)
BABA   94.48 (+14.79%)
NIO   16.03 (+9.49%)
AMD   98.75 (+6.58%)
CGC   5.55 (+10.34%)
MU   70.60 (+4.02%)
T   21.32 (+0.09%)
GE   77.01 (+3.33%)
F   13.12 (+3.23%)
DIS   105.61 (+2.28%)
AMC   12.23 (+2.95%)
PFE   53.99 (+0.52%)
PYPL   80.42 (+0.37%)
NFLX   191.40 (+1.90%)
NASDAQ:IMNP

Immune Pharmaceuticals (IMNP) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
12.29 million shs
Market Capitalization
$8.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Receive IMNP News and Ratings via Email

Sign-up to receive the latest news and ratings for Immune Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Immune Pharmaceuticals logo

About Immune Pharmaceuticals

Immune Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of various therapeutic agents for the treatment of immunologic and inflammatory diseases. The company's lead product candidate is bertilimumab, a human antibody, which is in Phase II clinical trials that targets eotaxin-1 for the treatment of bullous pemphigoid and ulcerative colitis. It is also developing NanoCyclo, a nano-encapsulated formulation of cyclosporine-A, which is in late stage preclinical development for atopic dermatitis and psoriasis. In addition, the company's pain products include AmiKet and AmiKet Nano, a topical analgesic cream containing amitriptyline and ketamine for the treatment of postherpetic neuralgia and diabetic peripheral neuropathy. Further, its oncology portfolio comprises Ceplene, for the maintenance of remission in patients with acute myeloid leukemia in combination with interleukin-2; Azixa and crolibulin that are clinical-stage vascular disrupting agents; NanomAbs, a nanotechnology combination platform; and bispecific antibody platform. Immune Pharmaceuticals, Inc. was founded in 2010 and is headquartered in Englewood Cliffs, New Jersey.

Headlines

Immune Pharmaceuticals Inc. (IMNP.ST)
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IMNP
Previous Symbol
OTCMKTS:EPCT
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$8.14 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/15/2018
Today
5/26/2022

MarketRank

Overall MarketRank

0.91 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Immune Pharmaceuticals (NASDAQ:IMNP) Frequently Asked Questions

How were Immune Pharmaceuticals' earnings last quarter?

Immune Pharmaceuticals Inc (NASDAQ:IMNP) posted its quarterly earnings data on Tuesday, May, 15th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.05.
View Immune Pharmaceuticals' earnings history
.

Who are Immune Pharmaceuticals' key executives?
Immune Pharmaceuticals' management team includes the following people:
  • Dr. Elliot M. Maza CPA, J.D., MBA, CPA, Pres, CEO, Principal Financial Officer, Principal Accounting Officer, Sec. & Director (Age 62)
  • Dr. Anthony S. Fiorino, COO & Chief Medical Officer (Age 51)
  • Mr. Christine J. Petraglia, Director of Investor Relations
  • Ms. Anna Baran-Djokovic J.D., Director of Corp. Affairs
  • Dr. Miri Ben-Ami, Pres of Immune Oncology Pharmaceuticals Inc
What other stocks do shareholders of Immune Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immune Pharmaceuticals investors own include Neovasc (NVCN), CytRx (CYTR), Biopharmx (BPMX), Synergy Pharmaceuticals (SGYP), Gevo (GEVO), Pernix Therapeutics (PTX), Sorrento Therapeutics (SRNE), Novavax (NVAX), DryShips (DRYS) and Heat Biologics (HTBX).

What is Immune Pharmaceuticals' stock symbol?

Immune Pharmaceuticals trades on the NASDAQ under the ticker symbol "IMNP."

How much money does Immune Pharmaceuticals make?

Immune Pharmaceuticals has a market capitalization of $0.00.

What is Immune Pharmaceuticals' official website?

The official website for Immune Pharmaceuticals is www.immunepharmaceuticals.com.

How can I contact Immune Pharmaceuticals?

Immune Pharmaceuticals' mailing address is 550 Sylvan Avenue, Englewood Cliffs NJ, 07632. The biopharmaceutical company can be reached via phone at 201-464-2677 or via email at [email protected].

This page was last updated on 5/26/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.